In a move that promises to redefine the trajectory of global biotechnology, China has introduced a transformative regulatory framework: Regulations on the Administration of Clinical Research and Clinical Translation and Application of Biomedical New Technologies, colloquially known as "Order 818."
By establishing a dual-pathway system for advanced therapeutics—including cell and gene therapies and gene-editing technologies—Beijing is signaling a strategic pivot. The order effectively creates a domestic "fast track" for innovation, allowing specific biomedical technologies to move from research to clinical application within premier hospitals without the traditional, often laborious, drug registration process required by the National Medical Products Administration (NMPA). As the global race for leadership in precision medicine intensifies, China’s latest legislative maneuver suggests an ambitious intent to standardize, industrialize, and accelerate its biotechnology sector.
The Core Mechanics of Order 818: A New Clinical Pathway
At the heart of Order 818 is the streamlining of clinical translation. Previously, the development of advanced therapies in China was a monolithic process, often mired in bureaucratic hurdles that delayed the bedside application of groundbreaking science.
Under the new mandate, therapeutics characterized by cellular or molecular mechanisms of action—often personalized or highly specific in nature—can be translated clinically at 3A hospitals. With approximately 1,700 such tertiary care facilities across the country, this represents a massive expansion of clinical infrastructure. Once a therapy receives translational approval, these institutions are permitted to administer the treatment to patients on a fee-for-service basis.
Defining the "Dual-Track" Reality
The industry is currently awaiting granular boundary-delineation guidelines to clarify the scope of this order. However, the emerging consensus among legal experts and industry analysts suggests a clear divide:
- The NMPA Track: Reserved for mass-marketed, standardized, or "off-the-shelf" therapeutics intended for broad distribution.
- The Order 818 Track: Tailored for bespoke, personalized therapeutics that do not fit the conventional mold of traditional drug manufacturing.
This duality is intended to provide a "risk observation window"—typically spanning one to five years—allowing for real-world evidence gathering before a technology migrates from the experimental track to the formal drug-registration track.
Chronology of Reform: From Fragmented Trials to Centralized Oversight
To understand the weight of Order 818, one must look at the evolution of China’s biotech regulatory environment over the last decade.
- Pre-2026 Era: Before the enactment of Order 818 on May 1, 2026, the landscape was highly decentralized. Biotech firms often relied on "investigator-initiated trials" (IITs), partnering with disparate medical institutions with varying levels of oversight. This created a "Wild West" environment that, while innovative, lacked the standardization required for global credibility and consistent safety protocols.
- May 1, 2026: Order 818 comes into force, establishing a centralized, standardized structure for hospital-based advanced therapy development.
- May 8, 2026: In a secondary, critical development, the National Health Commission released a consultation draft proposing a relaxation of human genetic resource (HGR) restrictions. The proposal suggests excluding protein, imaging, and clinical data from strict export controls, focusing regulatory scrutiny exclusively on nucleic acid sequence data.
- Future Outlook: The industry now awaits the formal integration of Order 818 with existing Foreign Investment Negative Lists, which currently constrain how multinational corporations (MNCs) participate in domestic development.
Supporting Data and Industry Perspectives
The reception from the biopharma industry has been cautiously optimistic. Experts view the policy as a pragmatic adjustment to the inherent complexities of personalized medicine.
"We definitely see this as a positive signal," notes Boyang Wang, founder of the Singapore-based global longevity fund Immortal Dragons. "Advanced therapeutics are intricate and often personalized; it is quite difficult for them to use the standard NMPA pathway. Order 818 provides a structure that ensures only high-caliber, capable hospitals are involved."
Jeremy Levin, PhD, chairman of Ovid Therapeutics and Opthera, and a veteran of global biotech policy, emphasizes that the move is part of a broader, systemic effort. "Advanced therapies such as CAR-T, cell therapy, and gene therapy require highly coordinated systems—regulatory clarity, manufacturing standards, hospital infrastructure, and quality oversight," Levin explains. "China is clearly trying to industrialize that environment."
Implications for Multinational Corporations (MNCs)
The regulatory shift necessitates a strategic audit for any international firm currently invested in the Chinese biotech market. The most immediate impact concerns contractual frameworks.
Redefining Milestone Clauses
Legal experts are warning that "legacy agreements"—contracts written for a single-pathway regulatory environment—are rapidly becoming obsolete. Todd Liao, a partner at Morgan Lewis & Bockius, stresses that if milestone payments are tethered exclusively to "NMPA approval," they may never be triggered for therapies transitioning through the hospital-based Order 818 pathway.
"We expect a wave of proactive contract amendments," says Liao. "If milestones are defined solely by NMPA events, a licensee commercializing a therapeutic through hospitals may never reach their financial targets. Companies must redefine these milestones around clinical and commercial outcomes, such as the ‘first fee-paying patient,’ rather than regulatory milestones."
The Data Export Conundrum
Despite the loosening of regulations regarding clinical and protein data, the issue of "human genetic resources" remains a major friction point. Under current laws, raw genetic data generally cannot leave Chinese soil. While analytical outputs may be permitted to cross borders, the nuances are subtle. For non-Chinese companies, the requirement to conduct research within 3A hospitals may inadvertently create data silos, complicating the global integration of trial results.
Strategic Challenges and the "Negative List"
While Order 818 offers a pathway to market, it exists within a larger, sometimes contradictory regulatory tapestry. The 2024 Foreign Investment Negative List continues to prohibit MNCs from certain types of investment in cell and gene therapy at a national level. While exceptions exist within specific Free Trade Zones (FTZs) like Beijing, Shanghai, and Hainan, these are currently predicated on the NMPA registration pathway.
The harmonization of these zones with the new Order 818 pathway remains an open question. Industry leaders are watching closely to see if the government will update the Negative List to reflect the reality of the new dual-pathway system.
Conclusion: A Long-Term Vision for Biotechnology
The overarching message from Beijing is clear: biotechnology is a pillar of national interest. By introducing Order 818, the government is not merely deregulating; it is attempting to create a sophisticated, predictable environment that can foster local innovation while attracting international capital and expertise.
"The overall regulatory direction is actually loosening, not tightening," observes Liao. "It is a move toward centralized oversight that actually creates more predictability."
For global players, the mandate is clear: success in China will no longer be determined solely by mastering the NMPA’s registration process. Instead, it will require a deep understanding of hospital-based clinical translation, a willingness to renegotiate legacy contracts to reflect new commercial realities, and a nuanced approach to the shifting landscape of human genetic data.
As China positions itself to compete at the highest levels of global biotechnology, Order 818 stands as a testament to the country’s intent to lead in the era of precision medicine. Whether this framework will stifle or accelerate global collaboration remains to be seen, but one thing is certain: the global biotech industry must adapt, or risk being sidelined in one of the world’s most dynamic and rapidly evolving markets.
